Cargando…

Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Report from the Canadian Myeloma Research Group (CMRG) Database

The treatment of multiple myeloma has dramatically improved due to the availability of novel therapies that are highly effective and are quickly moving into first-line therapy. The Canadian Agency for Drugs and Technologies in Health (CADTH) recently recommended that patients who receive daratumumab...

Descripción completa

Detalles Bibliográficos
Autores principales: McCurdy, Arleigh, Venner, Christopher P., Masih-Khan, Esther, Louzada, Martha, LeBlanc, Richard, Sebag, Michael, Song, Kevin, Jimenez-Zepeda, Victor H., Kotb, Rami, Kardjadj, Moustafa, Mian, Hira, White, Darrell, Stakiw, Julie, Aslam, Muhammad, Reiman, Anthony, Gul, Engin, Reece, Donna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946875/
https://www.ncbi.nlm.nih.gov/pubmed/35323332
http://dx.doi.org/10.3390/curroncol29030132
_version_ 1784674295918624768
author McCurdy, Arleigh
Venner, Christopher P.
Masih-Khan, Esther
Louzada, Martha
LeBlanc, Richard
Sebag, Michael
Song, Kevin
Jimenez-Zepeda, Victor H.
Kotb, Rami
Kardjadj, Moustafa
Mian, Hira
White, Darrell
Stakiw, Julie
Aslam, Muhammad
Reiman, Anthony
Gul, Engin
Reece, Donna
author_facet McCurdy, Arleigh
Venner, Christopher P.
Masih-Khan, Esther
Louzada, Martha
LeBlanc, Richard
Sebag, Michael
Song, Kevin
Jimenez-Zepeda, Victor H.
Kotb, Rami
Kardjadj, Moustafa
Mian, Hira
White, Darrell
Stakiw, Julie
Aslam, Muhammad
Reiman, Anthony
Gul, Engin
Reece, Donna
author_sort McCurdy, Arleigh
collection PubMed
description The treatment of multiple myeloma has dramatically improved due to the availability of novel therapies that are highly effective and are quickly moving into first-line therapy. The Canadian Agency for Drugs and Technologies in Health (CADTH) recently recommended that patients who receive daratumumab should only be eligible to receive either carfilzomib or pomalidomide but not both, for relapsed MM. In order to assess the efficacy of these two agents in the relapsed setting, we utilized our national myeloma database. A total of 121 patients were reviewed, 49 patients received CAR- before POM-based (CAR-POM), and 73 patients received POM- before CAR-based (POM-CAR) therapy. In the groups selected, the median PFS was 4.93 months (95% CI, 2.76–7.07) and 5.36 months (95% CI, 3.75–6.94) for CAR-POM and POM-CAR, respectively. The median OS for patients treated with CAR-POM was 11.01 months (95% CI, 4.50–19.13), and for patients treated with POM-CAR the median OS was 10.98 months (95% CI, 8.98–19.17). In this real-world observational study, we demonstrated that both CAR- and POM-based therapies, irrespective of the order in which they were used, were effective treatment options for patients with advanced relapsed MM.
format Online
Article
Text
id pubmed-8946875
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89468752022-03-25 Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Report from the Canadian Myeloma Research Group (CMRG) Database McCurdy, Arleigh Venner, Christopher P. Masih-Khan, Esther Louzada, Martha LeBlanc, Richard Sebag, Michael Song, Kevin Jimenez-Zepeda, Victor H. Kotb, Rami Kardjadj, Moustafa Mian, Hira White, Darrell Stakiw, Julie Aslam, Muhammad Reiman, Anthony Gul, Engin Reece, Donna Curr Oncol Brief Report The treatment of multiple myeloma has dramatically improved due to the availability of novel therapies that are highly effective and are quickly moving into first-line therapy. The Canadian Agency for Drugs and Technologies in Health (CADTH) recently recommended that patients who receive daratumumab should only be eligible to receive either carfilzomib or pomalidomide but not both, for relapsed MM. In order to assess the efficacy of these two agents in the relapsed setting, we utilized our national myeloma database. A total of 121 patients were reviewed, 49 patients received CAR- before POM-based (CAR-POM), and 73 patients received POM- before CAR-based (POM-CAR) therapy. In the groups selected, the median PFS was 4.93 months (95% CI, 2.76–7.07) and 5.36 months (95% CI, 3.75–6.94) for CAR-POM and POM-CAR, respectively. The median OS for patients treated with CAR-POM was 11.01 months (95% CI, 4.50–19.13), and for patients treated with POM-CAR the median OS was 10.98 months (95% CI, 8.98–19.17). In this real-world observational study, we demonstrated that both CAR- and POM-based therapies, irrespective of the order in which they were used, were effective treatment options for patients with advanced relapsed MM. MDPI 2022-03-02 /pmc/articles/PMC8946875/ /pubmed/35323332 http://dx.doi.org/10.3390/curroncol29030132 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Brief Report
McCurdy, Arleigh
Venner, Christopher P.
Masih-Khan, Esther
Louzada, Martha
LeBlanc, Richard
Sebag, Michael
Song, Kevin
Jimenez-Zepeda, Victor H.
Kotb, Rami
Kardjadj, Moustafa
Mian, Hira
White, Darrell
Stakiw, Julie
Aslam, Muhammad
Reiman, Anthony
Gul, Engin
Reece, Donna
Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Report from the Canadian Myeloma Research Group (CMRG) Database
title Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Report from the Canadian Myeloma Research Group (CMRG) Database
title_full Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Report from the Canadian Myeloma Research Group (CMRG) Database
title_fullStr Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Report from the Canadian Myeloma Research Group (CMRG) Database
title_full_unstemmed Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Report from the Canadian Myeloma Research Group (CMRG) Database
title_short Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Report from the Canadian Myeloma Research Group (CMRG) Database
title_sort sequential use of carfilzomib and pomalidomide in relapsed multiple myeloma: a report from the canadian myeloma research group (cmrg) database
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946875/
https://www.ncbi.nlm.nih.gov/pubmed/35323332
http://dx.doi.org/10.3390/curroncol29030132
work_keys_str_mv AT mccurdyarleigh sequentialuseofcarfilzomibandpomalidomideinrelapsedmultiplemyelomaareportfromthecanadianmyelomaresearchgroupcmrgdatabase
AT vennerchristopherp sequentialuseofcarfilzomibandpomalidomideinrelapsedmultiplemyelomaareportfromthecanadianmyelomaresearchgroupcmrgdatabase
AT masihkhanesther sequentialuseofcarfilzomibandpomalidomideinrelapsedmultiplemyelomaareportfromthecanadianmyelomaresearchgroupcmrgdatabase
AT louzadamartha sequentialuseofcarfilzomibandpomalidomideinrelapsedmultiplemyelomaareportfromthecanadianmyelomaresearchgroupcmrgdatabase
AT leblancrichard sequentialuseofcarfilzomibandpomalidomideinrelapsedmultiplemyelomaareportfromthecanadianmyelomaresearchgroupcmrgdatabase
AT sebagmichael sequentialuseofcarfilzomibandpomalidomideinrelapsedmultiplemyelomaareportfromthecanadianmyelomaresearchgroupcmrgdatabase
AT songkevin sequentialuseofcarfilzomibandpomalidomideinrelapsedmultiplemyelomaareportfromthecanadianmyelomaresearchgroupcmrgdatabase
AT jimenezzepedavictorh sequentialuseofcarfilzomibandpomalidomideinrelapsedmultiplemyelomaareportfromthecanadianmyelomaresearchgroupcmrgdatabase
AT kotbrami sequentialuseofcarfilzomibandpomalidomideinrelapsedmultiplemyelomaareportfromthecanadianmyelomaresearchgroupcmrgdatabase
AT kardjadjmoustafa sequentialuseofcarfilzomibandpomalidomideinrelapsedmultiplemyelomaareportfromthecanadianmyelomaresearchgroupcmrgdatabase
AT mianhira sequentialuseofcarfilzomibandpomalidomideinrelapsedmultiplemyelomaareportfromthecanadianmyelomaresearchgroupcmrgdatabase
AT whitedarrell sequentialuseofcarfilzomibandpomalidomideinrelapsedmultiplemyelomaareportfromthecanadianmyelomaresearchgroupcmrgdatabase
AT stakiwjulie sequentialuseofcarfilzomibandpomalidomideinrelapsedmultiplemyelomaareportfromthecanadianmyelomaresearchgroupcmrgdatabase
AT aslammuhammad sequentialuseofcarfilzomibandpomalidomideinrelapsedmultiplemyelomaareportfromthecanadianmyelomaresearchgroupcmrgdatabase
AT reimananthony sequentialuseofcarfilzomibandpomalidomideinrelapsedmultiplemyelomaareportfromthecanadianmyelomaresearchgroupcmrgdatabase
AT gulengin sequentialuseofcarfilzomibandpomalidomideinrelapsedmultiplemyelomaareportfromthecanadianmyelomaresearchgroupcmrgdatabase
AT reecedonna sequentialuseofcarfilzomibandpomalidomideinrelapsedmultiplemyelomaareportfromthecanadianmyelomaresearchgroupcmrgdatabase